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ABSTRACT  
One of the most common mitochondrial DNA (mtDNA) mutations, the A to G transition at 
base pair 3243, has been linked to changes in the brain, in addition to commonly observed hearing 
problems, diabetes and myopathy. However, a detailed quantitative description of m.3243A>G 
patients’ brains has not been provided so far. In this study, ultra-high field MRI at 7 Tesla and 
volume- and surface-based data analyses approaches were used to highlight morphology (i.e. 
atrophy)-, microstructure (i.e. myelin and iron concentration)- and metabolism (i.e. cerebral blood 
flow)-related differences between patients (N=22) and healthy controls (N=15). The use of 
quantitative MRI at 7 Tesla allowed us to detect subtle changes of biophysical processes in the brain 
with high accuracy and sensitivity, in addition to typically assessed lesions and atrophy. 
Furthermore, the effect of m.3243A>G mutation load in blood and urine epithelial cells on these 
MRI measures was assessed within the patient population and revealed that blood levels were most 
indicative of the brain’s state and disease severity, based on MRI as well as on neuropsychological 
data. Morphometry MRI data showed a wide-spread reduction of cortical, subcortical and cerebellar 
gray matter volume, in addition to significantly enlarged ventricles. Moreover, surface-based 
analyses revealed brain area-specific changes in cortical thickness (e.g. of the auditory cortex), and 
in T1, T2* and cerebral blood flow as a function of mutation load, which can be linked to typically 
m.3243A>G-related clinical symptoms (e.g. hearing impairment). In addition, several regions 
linked to attentional control (e.g. middle frontal gyrus), the sensorimotor network (e.g. banks of 
central sulcus) and the default mode network (e.g. precuneus) were characterized by alterations in 
cortical thickness, T1, T2* and/or cerebral blood flow, which has not been described in previous 
MRI studies. Finally, several hypotheses, based either on vascular, metabolic or astroglial 
implications of the m.3243A>G mutation, are discussed that potentially explain the underlying 
pathobiology. To conclude, this is the first 7T and also the largest MRI study on this patient 
population that provides macroscopic brain correlates of the m.3243A>G mutation indicating 
potential MRI biomarkers of mitochondrial diseases and might guide future (longitudinal) studies to 
extensively track neuropathological and clinical changes.  
 
KEYWORDS 
7T MRI, brain, quantitative, m.3243A>G, mitochondrial   
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ABBREVIATIONS 
15-WLT 15-Words Learning Task 
ADL Activities daily life 
ASL Arterial spin labeling 
CBF Cerebral blood flow 
cGM Cortical gray matter 
CSF Cerebral spinal fluid 
CN Caudate nucleus 
CNR Contrast-to-noise ratio 
DN Dentate nucleus 
EPI Echo planar imaging 
eTIV Estimated total intracranial volume 
FWHM Full-width half maximum 
GP Globus pallidus 
GM Gray matter 
IQR Interquartile range 
Leu Leucine 
LDST Letter-Digit Substitution test 
NMDAS Newcastle Mitochondrial Disease Adult Scale 
MANOVA Multivariate analysis of variance 
MELAS Mitochondrial encephalopathy lactic acidosis and stroke-like episodes 
MIDD Mitochondrial inherited deafness and diabetes 
mtDNA Mitochondrial DNA 
OXPHOS Oxidative phosphorylation 
Pu Putamen 
RF Radio frequency 
RN Red nucleus 
ROI Region of interest 
SLEs Stroke-like cortical episodes 
SN Substantia nigra 
SNR Signal-to-noise ratio 
T Tesla 
UECs Urine epithelial cells 
UHF Ultra-high field 
WM White matter 
WMLs White matter lesions 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Neural correlates of m.3243A>G mutation load 
4 
 
1. INTRODUCTION  
The brain contributes to about 20% of the human body’s energy consumption (Magistretti 
and Allaman, 2015; Sokoloff et al., 1977). Mitochondria serve as the biological units that utilize 
oxygen and glucose through oxidative phosphorylation to produce ATP from ADP (adenosine 
diphosphate). Approximately 4.7 billion ATP molecules per second are used by a single cortical 
neuron in a resting human brain, illustrating the extremely high energy demand of the brain (Zhu et 
al., 2012). As a result, a reduced energy production due to mitochondrial dysfunctioning may affect 
neuronal and glial integrity, leading to changes in the brain's structure and functioning (Keogh and 
Chinnery, 2015). For example, using MRI, qualitative cortical, white matter, brainstem and 
cerebellar morphological changes were observed in patients with respiratory energy chain defects 
(Saneto et al., 2008). In addition, changes are observed related to the homeostasis of biochemical 
compounds (such as iron, myelin and calcium), as particularly highlighted by deep gray matter MRI 
signal intensity changes (Dinopoulos et al., 2005). 
 
Mitochondrial dysfunctioning can be caused by mutations in the mtDNA. Germline 
mutations can either occur de novo or be inherited from the mother. These mutations can be either 
homoplasmic, i.e. all mtDNA copies mutated, or heteroplasmic, i.e. a mixture of mutated and wild-
type mtDNA. For heteroplasmic mutations, the mutation load may differ among different tissue 
types. As mitochondria are present in most eukaryotic cell types, mitochondrial mutations lead to a 
wide-range of symptoms, affecting multiple systems in the body, especially those with a high 
energy requirement, including the central nervous system (Lightowlers et al., 2015). 
 
 One of the most common mtDNA mutations is the m.3243A>G mutation within the 
mtDNA-encoded tRNA leucine 1 (MTTL1) gene (Goto et al., 1990), affecting proper incorporation 
of the amino acid leucine in mtDNA encoded proteins. The m.3243A>G mutation causes a broad 
variety of clinical manifestations, of which the MELAS or MIDD syndromes are the most common 
(i.e. 10% and 38% of m.3243A>G carriers, respectively). These patients are characterized by a wide 
range of phenotypic expressions, but most often suffer from sensorineural (due to dysfunctioning 
cochlear hair cells or nerve) hearing loss (51%), diabetes (42%) and proximal myopathy (27%) 
(Nesbitt et al., 2013). m.3243A>G specific brain symptoms are (transient) SLEs, visible as T2 MRI 
signal hyperintensities and characterized by an increased CBF, as measured using ASL. Increased 
CBF is detected both before (Ikawa et al., 2013) and after onset of SLEs (Li et al., 2017), possibly 
to counterbalance observed neuronal hyperexcitability and pathology (Iizuka et al., 2002). Since 
SLEs are an important feature of the brain pathology in m.3243A>G patients, several studies have 
attempted to characterize the pathogenesis, as well as the temporal and spatial progression of these 
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lesions. For example, these studies have shown locally increased lactate levels (Tsujikawa et al., 
2010), but also a reduced apparent diffusion coefficient and cortical laminar necrosis (Iizuka et al., 
2003). In addition, increased baseline CBF was observed in m.3243A>G patients without SLEs 
(Rodan et al., 2015).  
However, not all patients fall within the ‘standard’ disease criteria, leading to sub-optimal 
and delayed diagnosis and prognosis. Several attempts have been made to link m.3243A>G 
mutation load in different tissue types (e.g. skeletal muscle, blood leukocytes and urine) with 
disease severity (based on, for example, number of symptoms or severity scores) to predict clinical 
prognosis (Chinnery et al., 1997; de Laat et al., 2012; Whittaker et al., 2009). Mutation load in 
UECs was preferred, based on its (1) strong correlation with clinical parameters, (2) stability 
throughout life and (3) non-invasive assessment. Based on the above criteria, it is evident that the 
m.3243A>G mutation induces a large diversity of symptoms, including different types of brain 
changes. While the severity of the phenotype may depend on mutation load, no previous study 
focussed on the mutation load-brain relationship in m.3243A>G patients. Thus, it is not clear how 
the mutation load is associated with cortical, subcortical and cerebellar pathologies on microscopic 
and macroscopic levels and how those relate to the individual’s clinical symptoms. 
 
 In the present neuroimaging study, we aim to quantify the relationship between the 
m.3243A>G mutation load percentage and brain phenotype in a large group of patients (N=22) and 
healthy controls (N=15) using UHF 7T MRI. State-of-the-art quantitative brain imaging and 
analysis approaches are utilized that enable a direct comparison between groups and within patients, 
with a focus on the brain's morphological (e.g. brain volume and cortical thickness), 
microstructural-related (T1 and T2* relaxometry) and metabolism-related (CBF) properties. More 
specifically, we investigate (1) the relationship between (sub-)cortical and cerebellar atrophy with 
the m.3243A>G genotype (i.e. no mutation vs. low to high mutation load) and (2) the potential 
differences in myelin- and iron-sensitive T1, T2*, as well as CBF, colocalising with the 
morphological changes in patients.  
 
The relative gain in SNR at 7T compared to clinical 1.5T and 3T depends on the MRI 
contrast used (Norris, 2003; Pohmann et al., 2016; Vaughan et al., 2001). For CBF using ASL the 
gain is approximately linear for high-resolution studies (e.g. below 2 mm isotropic). For example, in 
the study of Ivanov et al. (2017a), 7T outperformed 3T by a factor of ~1.75 at 1.5 mm in-plane 
resolution for CBF data. For susceptibility contrasts, such as T2* and functional MRI, the gain can 
be more than linear. Uludag and Blinder (2017)have theoretically estimated that the SNR of fMRI at 
high spatial resolution scales approximately quadratically with magnetic field strength. For T1 
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contrast, however, a signal gain is only expected for very high resolution, higher than typically 
utilized in in vivo human studies.  
Several studies already provided clear evidence of the enhanced detection of disease-specific 
morphological changes in the brains of, for example, multiple sclerosis and Alzheimer’s disease 
patients using 7T compared to 3T (Kollia et al., 2009; Nakada et al., 2008). Studies, comparing 
lower to UHF-MRI for a wide range of clinical applications, have been discussed recently by 
Trattnig et al. (2016). Here, the improved SNR for 7T enriches the images with spatial details not 
visible at lower field strengths due to the possibility to acquire data with a higher resolution and 
CNR, but without increasing the scan time (Duyn et al., 2007). As a result, 7T imaging exhibits 
increased diagnostic power due to enhanced sensitivity to detect fine-scale structural (Keuken et al., 
2017; Stuber et al., 2014), perfusion (Gardener et al., 2009; Ivanov et al., 2017a) and functional 
(Pfeuffer et al., 2002; Uludag and Blinder, 2017; Yacoub et al., 2008) properties and changes in the 
brain, see also recent reviews by van der Zwaag et al. (2016) and Ugurbil (2017). As such, the 
current results contribute to a better understanding of the disease pathology and classification of 
m.3243A>G patients, in particular, and mitochondrial disease patients, in general. 
 
2. MATERIALS & METHODS 
2.1. Participants 
 Twenty-two m.3243A>G patients and fifteen healthy age-, gender- and education-matched 
controls were included in this study after providing written informed consent in accordance with the 
Declaration of Helsinki. The protocol was approved by the ethics review board of the MUMC+ in 
Maastricht, The Netherlands. We included patients only when they were ADL-independent, as 
measured using the Barthel disability index and had a score <30 on the NMDAS (Schaefer et al., 
2006). We used three (current function, system specific involvement, and current clinical 
assessment) out of the four NMDAS sections, which resulted in a spectrum with less severe 
phenotypes to demonstrate the usefulness of quantitative MRI at 7T for detecting brain changes 
beyond lesions and atrophy, as it is typically assessed in imaging studies. For this reason, patients in 
the acute phase and/or with a history of SLEs were excluded. For severe phenotypes (i.e. Barthel 
index <15 and/or NMDAS >30), the brains of m.3243A>G patients strongly deviate from those of 
age-matched controls, already detectable with standard MRI methods at 1.5 and 3T. Patients were 
only eligible for inclusion after evaluation of the clinically-relevant symptoms by an experienced 
clinician (I.F.M.d.C, see Fig. 1c for an overview of the symptoms). Patients with metallic implants 
(e.g. cochlear or stents) were excluded, as these would interfere with the magnetic field of the MRI 
scanner. Assessed parameters were: (1) m.3243A>G mutation loads (%) in blood and UECs 
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following the procedure described in (Sallevelt et al., 2013), (2) fasting blood glucose (mmol/L) and 
HbA1c (% and IFCC) levels measured using standard procedures and (3) cognitive performance 
scores. Several cognitive domains were assessed using the visual 15-WLT to test memory, recall 
and recognition (Van der Elst et al., 2005), the Stroop colour-word test to test attention (Van der Elst 
et al., 2006b) and the LDST to test information processing speed (van der Elst et al., 2006a). Raw 
test scores were Z-scored based on the average control scores for each cognitive task (see Table 1). 
 
2.2. Data acquisition 
 MRI data were acquired using a whole-body 7T magnet (Siemens Medical Systems, 
Erlangen, Germany) and a 32-channel phased-array head coil (Nova Medical, Wilmington, MA, 
USA). High resolution (0.7 mm isotropic nominal voxel size) whole-brain quantitative T1 and T2* 
images were obtained with MP2RAGE (Marques et al., 2010) and ME-GRE sequences, 
respectively. The SA2RAGE (Eggenschwiler et al., 2012) sequence was used to map B1+ across the 
brain. In addition to the anatomical scans, baseline partial-brain (excluding cerebellum and lower 
temporal lobes) perfusion was quantified using FAIR QUIPSS II ASL (Ivanov et al., 2017b). The 
eye centres were taken as reference for the magnet isocenter position to improve the ASL labelling 
efficiency. See Supplementary Table 1 for the relevant sequence parameters. In addition, a standard 
dual-echo field map was acquired to correct the ASL data for EPI readout-related geometrical 
distortions. Dielectric pads containing a 25% suspension of barium titanate in deuterated water were 
placed proximal to the temporal lobe areas to locally increase the transmit B1+ field and to improve 
its homogeneity across the brain (Teeuwisse et al., 2012). 
 
2.3. Surface-based analyses 
Images were pre-processed to improve subsequent automatic volume- and surface-based 
processing. An extensive description of the pipeline can be found in the Supplementary Methods 1. 
The pre-processing included brain masking, post-hoc T1 correction and computation of T2* and 
ASL maps. Cortical reconstruction and submillimeter volumetric segmentation was then performed 
with the FreeSurfer (v6.0, http://surfer.nmr.mgh.harvard.edu/) image analysis suite using the pre-
processed  MP2RAGE UNI images as input (Dale et al., 1999). Manual corrections of the tissue 
classifications were performed when necessary. Boundary-based registration (i.e. 'bbregister') was 
used to co-register the T2* and CBF maps to the MP2RAGE data with a 6 DOF transformation and 
spline interpolation. In addition, the fieldmap was used to correct for EPI readout geometrical 
distortions and improve the co-registration of the CBF map, particularly near the sinuses. Co-
registered CBF maps were then corrected for partial volume effects by dividing it with a GM 
probability map obtained using SPM12 (http://www.fil.ion.ucl.ac.uk/spm). For each subject, all 
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modalities were projected onto the surface using FreeSurfer’s mri_vol2surf function by averaging 
between 20 and 80% of the cortical thickness (with steps of 0.05%) to reduce potential partial 
voluming with WM and CSF. In addition, WM surface maps were computed by averaging between 
-0.5 mm and -2 mm distance (with steps of 0.05 mm) from the WM-GM boundary. All surface 
maps, including surface-based morphology metrics generated by FreeSurfer (e.g. cortical volume 
and thickness), were coregistered to the ‘fsaverage’ subject using sphere-based alignment (Fischl et 
al., 1999) and smoothed with FWHM = 10 mm for further statistical analyses. Final surface maps 
were visualized using the Connectome Workbench v1.2.3 viewer (Washington University School of 
Medicine, Saint Louis, MO, USA) after conversion of the inflated surfaces and overlays to a 
compatible format. Non-cortical tissue in between the hemispheres was masked using FreeSurfer’s 
parcellation scheme to avoid inappropriate scaling of the surface maps. 
 
2.4. Volume-based analyses 
 In addition to the surface-based data, volumetric data were assessed for subcortical 
structures and cerebellum. For the CN, GP and Pu, the automatic subcortical parcellation by 
FreeSurfer (Fischl et al., 2002) was manually corrected by taking into account the microstructural 
information (i.e. the values) from both the quantitative T1 and T2* maps using ITK-SNAP v3.6.0 
(Yushkevich et al., 2006). In addition, RN, SN and DN were semi-automatically delineated, 
navigated by a threshold-based approach implemented in ITK-SNAP. The cerebellar segmentation 
tool (CERES) was utilized to accurately segment the cerebellum into GM and WM (Romero et al., 
2017). Final subcortical and cerebellar labels were used to export volume (mm3) and average T1, 
T2* and CBF values for each of the structures to MATLAB and/or SPSS for further statistical 
analyses. 
 
2.5. Statistical analyses 
 Descriptive participants’ characteristics are reported as mean ± standard deviation (S.D.), 
while the median and IQR (25th and 75th percentiles) are shown for the NMDAS. Between-group 
(controls vs. m.3243A>G) demographic characteristics were tested by use of independent 2-sample 
t-tests (continuous data) or Pearson χ2-tests (categorical data) with SPSS (Statistical Package for 
Social Sciences, version 23, IBM Corp., USA) and α = 0.05.  
  
For the volumetric data, a MANOVA test with Bonferroni correction was conducted to 
compare cGM, WM, subcortical GM (global or per structure) and cerebellar GM and WM volumes, 
T1, T2* and CBF between groups. Each patient was assigned to one of two groups based on 
mutation load. However, due to differences in mutation load across tissue types (and, in blood, also 
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with age, see for example de Laat et al. (2012)), it is difficult to predefine the pathogenic threshold 
level (Chomyn et al., 1992) for brain tissue based on the blood and/or UEC data. Therefore, the 
median was used as classifier within the entire patient population. This was based on pragmatic 
reasons (i.e. to have equal sub-group sizes with comparable statistical power) in order to perform 
group-wise analyses (besides correlation). In addition, linear regression analysis was used to 
explore the relationship between mutation load and the structures volumes, T1, T2* and CBF, and 
was therefore restricted to m.3243A>G patients. All tests were corrected for age, gender and eTIV.  
 
For the cortical surface data, a two-step analysis approach was used, due to the high clinical 
variability between the m.3243A>G patients, for detection of (1) within- and (2) between-group 
brain differences. First, a whole-brain vertex-wise linear regression analysis was performed to 
detect clusters of vertices, for which cortical thickness (as measure of cortical atrophy), T1, T2* and 
CBF are significantly negatively or positively correlated with mutation load (in blood) in 
m.3243A>G patients. Here, age and gender were used as nuisance variables and corrected for 
multiple comparisons (i.e. number of vertices in left and right hemispheres) using Monte Carlo 
Null-Z simulation with a voxel-wise threshold of 2.0 (cluster-wise p-value of <0.01). A more 
lenient cluster-wise p-value of <0.05 was used for T1, T2* and CBF in a separate, additional analysis 
to also highlight subtle, but still significant, changes as a function of mutation load. This was 
motivated by the hypothesis that T1, T2* and CBF differences do not per se have to concur with, but 
can also pre- and/or proceed cortical thickness alterations. Second, significant clusters (per 
parameter) were then used to compare between groups using an ANOVA test, corrected for age and 
gender.  
 
3. RESULTS 
 The healthy control subjects (N=15) were matched to the m.3243A>G patients (N=22) on 
the basis of age (Pearson χ2 test, p=0.487), gender (p=0.538) and educational level (p=0.838), see 
Table 1. Significant higher fasting glucose (ANOVA, F1,32=11.14, p=0.002) and HbA1c 
(F1,32=12.75, p=0.001) levels were detected in m.3243A>G patients compared to controls, after 
accounting for age, gender and BMI (body mass index). The Barthel index was, except for one 
patient with a score of 16 (i.e. moderate to good self-supporting), maximal. Scores for the NMDAS 
ranged between 0 and 26 with a median score of 8.5 (IQR=4-13).   
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Table 1 – Main characteristics of healthy controls and m.3243A>G patients. Values represent mean (± S.D.) if not 
stated otherwise. 
 Controls (n = 15) m.3243A>G patients (n = 22) P-value 
Demographics    
Age, yr 38.40 (14.24) 41.23 (10.29) 0.487 
Sex, % women 73.3 81.8 0.538 
BMI, kg/m2 24.43 (4.24) 23.04 (3.59) 0.289 
Education, scale1 5.20 (1.21) 5.09 (0.92) 0.838 
Glucose status    
Fasting glucose, mmol/L 4.99 (0.45) 6.56 (1.70) 0.001† 
HbA1c, % 5.02 (0.64) 6.55 (1.24) <0.001† 
HbA1c, IFCC 31.20 (7.21) 45.36 (12.40) <0.001† 
Clinical-relevant symptoms    
Mutation load    
UECs, % 0 53.14 (26.09) - 
Blood, % 0 20.23 (11.40) - 
Barthel index - 19.82 (0.83) - 
NMDAS - 8.50 (4 – 13)  - 
Number of symptoms 0 3.64 (2.46) - 
See Fig. 1C for more details 
Cognitive performance    
MMSE 29.13 (1.30) 28.27 (2.47) 0.226 
LDST, z-score 0 (1.0) -1.08 (2.18) 0.083 
Stroop, z-score    
Words only 0 (1.0) 0.62 (1.35) 0.054 
Colours only 0 (1.0) 0.95 (1.63) 0.081 
Words and colours 0 (1.0) 1.40 (2.89) 0.127 
15-WLT, z-score    
Total  0 (1.0) -0.38 (1.04) 0.282 
Recall 0 (1.0) 0.01 (0.99) 0.973 
Recognition 0 (1.0) -0.84 (3.01) 0.310 
Abbreviations: BMI = body mass index; UEC = urinary epithelial cells; NMDAS = Newcastle Mitochondrial Disease 
Adult Scale; MMSE = mini-mental state examination; LDST = letter-digit substitution task; 15-WLT = 15-words 
learning task. 1Educational scale ranges from 1 (no education) to 8 (university). †ANOVA, corrected for age, gender 
and BMI. 
 
3.1. m.3243A>G clinical characteristics 
 The mutation load in blood was significantly correlated with the mutation load in UECs 
(Pearson correlation, r18=0.757, p<0.001, see Fig. 1A) and was on average 2.95 (±1.40) times lower 
than in UECs. The median m.3243A>G percentage in blood of 23% was used to subdivide patients 
in Plow (<23%, filled dots in Fig. 1A) or Phigh (≥23%, empty dots). Correlation analyses revealed that 
both the mutation loads in blood (r18=0.473, p=0.035, see Fig. 1B) and UECs (r18=0.550, p=0.012, 
not shown) are positively correlated (after correcting for age and gender) with the NMDAS score. 
Increasing mutation load in blood, not UECs, was correlated with worse cognitive test 
performances for the LDST (Pearson correlation, r18=-0.745, p=0.005) and Stroop tasks (r18=0.599, 
p=0.025, not shown), corrected for age, gender and education. 
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Figure 1 – Correlation analysis between clinical and genetic data. Scatter plots show the correlation between 
m.3243A>G mutation load (%) measured in UECs and blood (A) and the age- and gender-adjusted correlation between 
mutation load in blood and NMDAS score (B). Filled and empty dots represent Plow and Phigh patients, respectively. 
Solid lines represent the best fit ± 95% CIs. Boldface p-values indicate a significant correlation. Spiderplot visualizes 
the prevalence of each symptom within both the Plow (solid line) and Phigh (dashed line) m.3243A>G patient groups (C). 
Diabetes was true in case of known history from physician and HbA1c (IFCC) level higher than 45. Low weight was 
true in case of a BMI lower than 18.50.  
 
 Hearing loss was the most prevalent observed symptom within the m.3243A>G patient 
group (Plow vs. Phigh: 50 vs. 75%), as can be observed in Fig. 1C. This was followed by diabetes 
mellitus (60 vs. 58.3%), exercise intolerance (30 vs. 75%) and tiredness (40 vs. 66.7%). Migraine 
(30 vs. 41.7%) and muscle cramps (10 vs. 41.7%) are moderately observed, while cardiomyopathy 
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(10 vs. 25%), underweight (0 vs. 33.3%), cognitive decline (10 vs. 16.7%), epilepsy (10 vs. 8.3%), 
swallowing problems and SLEs (both 0 vs. 8.3%) are only observed in few patients. There was a 
significantly higher prevalence of exercise intolerance (Pearson χ2 test, p=0.035) in the Phigh group 
compared to the Plow group. 
 
3.2. Global brain morphology  
 Example quantitative T1, T2* and CBF maps for a control subject and an m.3243A>G 
patient of comparable age (66 vs. 67 yrs. old) are depicted in Fig. 2 across several axial slices. Note 
that, because we acquired quantitative MRI parameters, we can choose the same absolute scale for 
all subjects allowing us to examine quantitative MRI differences in addition to local contrast 
differences, typically indicative of lesions and atrophy. Clear signs of WMLs (see dashed blue box) 
were visible in both the patient’s T1 and T2* maps and were characterized by increased T1 and T2* 
relaxation times. In addition, a larger sulcal cerebrospinal fluid volume (i.e. increased space 
between neighbouring gyri) was visible for the patient, suggesting gray and/or white matter volume 
loss. In addition, with respect to the cerebellum, larger inter-folial spaces were visible for several 
patients (not shown). Possible differences regarding (sub)cortical perfusion (bottom row) were more 
difficult to detect visually and needed quantitative analysis. Therefore, we examined the normalized 
T1, T2* and CBF distributions for both cGM and WM tissue. Both cGM and WM T1 showed a 
significant increase as a function of mutation load (see Supplementary Fig. 1).  
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
Neural correlates of m.3243A>G mutation load 
13 
 
 
Figure 2 – Example MRI data. T1 (msec, A), T2* (msec, B) and CBF (ml/100 gr/min, overlaid onto the T1 map, C) maps are shown for a single control subject (left, age = 66 yr, M) 
and m.3243A>G patient (right, age = 67 yr, F). White matter lesions are highlighted by the dashed blue box and z-coordinates are shown (MNI-space) as reference. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Neural correlates of m.3243A>G mutation load 
14 
 
The total volume (in mm3, including left and right hemispheres, corrected for eTIV) was 
computed for each structure (cGM, ventricles, subcortical GM and cerebellar GM, see Figs. 3A-D, 
respectively) to characterize the morphological differences between groups. WM and cerebellar 
WM volumes are shown in Supplementary Figs. 2A and B, respectively. Significantly different 
brain volumes were detected across groups (MANOVA, Wilks’ Lambda=0.438, F12,54=2.298, 
p=0.019). Here, the cGM as well as the WM volume were significantly different between groups 
(F2,32=7.783, p=0.002 and F2,32=5.090, p=0.012, respectively). Similarly, group differences were 
observed for the ventricles (F2,32=4.101, p=0.026) and subcortical (F2,32=5.670, p=0.008) and 
cerebellar GM (F2,32=8.506, p=0.001) volumes, but not for the cerebellar WM volume. Significant 
differences were only found when comparing the control subjects with the Phigh group (p=0.002 for 
cGM, p=0.010 for WM, p=0.024 for the ventricles, p=0.035 for subcortical GM, p=0.001 for 
cerebellar GM) but not with the Plow group, except for the subcortical GM (p=0.021). Significant 
correlations were observed between mutation load and each structure’s volume (Pearson 
correlation, r18=-0.282, p=0.005 for cGM, r18=-0.228, p=0.024 for WM, r18=-0.604, p=0.008 for the 
ventricles and r18=-0.074, p=0.008 for cerebellar GM) across patients, except for the subcortical 
GM and cerebellar WM. Note that we did not correct for fasting glucose status, as this did not 
significantly affect the structures’ volume within the patient group. Finally, no differences were 
observed across groups with regards to eTIV. 
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Figure 3 – Between and within (i.e. mutation load effect) group comparison of the brain structure’s volumes. Bar plots display unadjusted mean (± S.D.) volumes for total gray 
matter (A), ventricles (B), subcortical (C) and cerebellar (D) gray matter volumes for controls (black) and P low (filled red) and Phigh (dashed red bars) mutation load in blood. 
Boldface p-values indicate a significant difference between groups after correction for age, gender and multiple comparisons. Scatterplots show the correlation between volume and 
mutation load in blood for m.3243A>G patients (Plow: filled and Phigh: empty red dots), adjusted for age and gender. Mean volume for each control subject (black dots) are displayed 
for reference and red solid lines represent the best fit ± 95% CIs. Boldface p-values indicate a significant correlation between mutation load in blood and volume after correcting for 
age and gender. 
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3.3. Fine-scale cortical morphology, microstructure and perfusion 
Several cortical ROI clusters of vertices showed a significant (cluster-wise p-value of <0.01) 
negative correlation between cortical thickness and mutation load in blood, see Fig. 4A (delineated 
by yellow lines). In general, the clusters encompassed regions predominantly within (respective to 
the FreeSurfer’s annotation) the middle frontal gyri, parietal (including precuneus) and superior 
temporal lobes. Strikingly, no significantly correlated clusters remained after multiple comparison 
correction when repeating the same analyses using mutation load in UECs. Similar analyses were 
performed using T1, T2* or CBF instead of cortical thickness (see Figs. 4B-D, respectively). T1 and 
T2* increased as a function of mutation load (cluster-wise p-value of <0.05) in pre- and post-central 
sulci, as well as in the occipital lobes, precuneus and insula for T2*. Increasing CBF was found in 
the superior frontal sulcus. To visualize the overlap of the findings using the different MRI 
modalities, significant clusters (vertex-value=1) were summed and color-coded, ranging between 1 
(green)-4 (purple), see Fig. 4E. Most overlap was observed near the central sulci, frontal gyri, 
occipital lobes and precuneus.  
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Figure 4 – Surface-based MRI data analysis. Vertex-wise linear regression analyses between mutation load in blood 
and cortical thickness (A), T1 (B), T2* (C) and CBF (D) within the m.3243A>G patients. Statistical z-maps, overlaid 
onto the left and right inflated (unfolded) surface reconstructions, show the vertices where cortical thickness 
(negatively), T1, T2* or CBF (positively) correlated with mutation load (after correction for age and gender). Significant 
clusters that remained after cluster-wise multiple comparison correction are delineated by yellow borders. Clusters were 
summarized across parameters by color-coding (1, green, to 4, purple) vertices based on the number of significant 
clusters (E). 
 
Z-scores were computed per cluster for each parameter and subsequently averaged to 
compare across groups. Group-wise averages revealed a significant lower cortical thickness in the 
m.3243A>G patients (including both Plow and Phigh patients, ANOVA, F1,33=5.646, p=0.023) 
compared to controls (see Fig. 5A). No significant differences were observed across groups for the 
T1, T2* and CBF data (see Figs. 5B-D), but compared to the controls, lower T1 was observed for 
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Plow, while a slightly higher T1 is observed for Phigh. A similar, but less apparent, pattern was 
observed for the T2* and CBF data.  
 
 
Figure 5 - Between group comparison of significant clusters. Dot plots display unadjusted mean (± S.D) cGM 
thickness (A), T1 (B), T2* (C) or CBF values (D), across corresponding significant clusters in Fig. 4, for controls 
(black), Plow (filled red) and Phigh (empty red dots). Boldface p-values indicate a significant difference between groups 
after correction for age, gender and multiple comparisons.  
 
Analogous to cGM, subcortical (i.e. alongside the cGM clusters) WM T1 and T2* were 
compared across groups (see Supplementary Fig. 2A). WM T1 and T2* were not significantly 
different across groups. However, WM T2* increased with mutation load in blood within the 
m.3243A>G patients (Pearson correlation, r18=0.454, p=0.044). Similarly, a trend was observed for 
WM T1 (r18=0.421, p=0.065). 
 
3.4. Subcortical and cerebellar morphology, microstructure and perfusion 
Reduced subcortical GM volume was observed for both the Plow and Phigh groups compared 
to the controls, but no effect of mutation load (see Fig. 3D). Group-averaged volumes for each 
subcortical structure (see Fig. 6A) individually are plotted (see Fig. 6B) and highlights significantly 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Neural correlates of m.3243A>G mutation load 
19 
 
reduced volume in the m.3243A>G patients compared to controls (MANOVA, Wilks’ 
Lambda=0.616, p=0.025) for the Pu (F1,33=8.959, p=0.005) and GP (F1,33=4.621, p=0.039). No clear 
microstructural changes, i.e. between groups or as function of mutation load, in the subcortical 
structures were present. However, several patients showed signs of spongiotic lesions in the Pu and 
GP that were characterized by high T1 and T2*, locally (see for example Fig. 6A for one subject). 
CBF increased with mutation load (Pearson correlation, r18=0.489, p=0.029).  
 
 
Figure 6 – Between and within group comparison of subcortical structures. ROIs (1=RN, 2=SN, 3=CN, 4=Pu, 
5=GP and 6=DN) are displayed schematically in A. Mean subcortical gray matter volume (B) and T1, T2* and CBF (C) 
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are compared across groups (controls: filled black, Plow: filled red and Phigh: dashed red bars) per ROI. Scatterplots 
display the correlation between mean (z-scored relative to controls and averaged across ROIs) T1, T2* and CBF vs. 
mutation load in blood (D). Mean values for controls (black dots) are displayed for reference and red solid lines 
represent the best fit ± 95% CIs. Boldface p-values indicate a significant correlation between mutation load in blood and 
cortical thickness, T1, T2* or CBF after correction for age and gender. 
 
 More pronounced effects were observed for cerebellar GM (see Fig. 7). Here, T1 was 
significantly higher for m.3243A>G (ANOVA, F1,33=12.947, p=0.001) and especially for the Phigh 
group compared to controls (F2,32=9.915, p<0.001, see Fig. 7A, top row). Moreover, T1 increases as 
a function of mutation load (r18=0.485, p=0.030, see Fig. 7B). In contrast, T2* was comparable 
across groups and did not correlate with mutation load. Similar but fewer significant findings were 
shown for cerebellar WM (see Supp. Fig. 2B).  
 
 
Figure 7 – Between and within group comparison of cerebellar GM. Dot plots in A display unadjusted mean (± 
S.D.) cerebellar GM T1 (top) or T2* (bottom) values for controls (black), Plow (filled red) and Phigh (empty red dots). 
Boldface p-values indicate a significant difference between groups after correction for age, gender and multiple 
comparisons. Scatterplots in B show the correlation between T1 or T2* and mutation load in blood for m.3243A>g 
patients (Plow: filled and Phigh: empty red dots), adjusted for age and gender. Mean T1 or T2* for each control subject 
(black dots) are displayed for reference and red solid lines represent the best fit ± 95% CIs. Boldface p-values indicate a 
significant correlation between mutation load in blood and cerebellar T1 or T2* after correction for age and gender. 
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4. DISCUSSION 
Mitochondrial dysfunctioning, either induced by acquired damage throughout life (such as 
by nucleases and reactive oxygen species) and/or by de novo or maternally inherited germline 
variations of the mtDNA, has been consistently linked to neurodegeneration (Keogh and Chinnery, 
2015). While several mtDNA mutations are known to affect the brain (Reeve et al., 2008), the 
current study focussed on the effects of the m.3243A>G genotype (i.e. mutation load) on the brain 
tissue using multiple parametric maps acquired with 7T MRI and compared these data to values 
obtained on healthy controls. 
 
4.1.  Mutation load and clinical characteristics 
 In the current study, we assessed mutation loads in both UECs and blood. Despite the 
mutation load in blood (leukocytes) being significantly lower compared to that in UECs, albeit 
comparable to that observed in earlier studies (Fayssoil et al., 2017; Shanske et al., 2004; Whittaker 
et al., 2009), both measures strongly correlated (de Laat et al., 2012; Frederiksen et al., 2006). It is 
known that the mutation load in blood decreases over lifetime with a constant rate of 1.4% per year 
(Rahman et al., 2001), while the mutation load in UECs is considered to be more consistent with 
age. Here, the loss of the m.3243A>G mutation in blood presumably originates from a selection 
against pathogenic mtDNA mutations in a stem cell population (Rajasimha et al., 2008).  
 
Hearing loss was the most prevalent symptom within the current study population, followed 
by exercise intolerance and diabetes mellitus. This matches with the MELAS and MIDD-like 
phenotypes associated with the m.3243A>G mutation and is in line with previous findings, 
reporting comparable numbers across their study cohorts (de Laat et al., 2012; Fayssoil et al., 2017; 
Nesbitt et al., 2013). In addition, we found a significant correlation between mutation load (in blood 
and UECs) and NMDAS score, as also shown in previous studies (de Laat et al., 2012; Whittaker et 
al., 2009). The observed differences between the Plow and Phigh groups in terms of symptoms 
prevalence, especially in the myopathy-related symptoms (e.g. exercise intolerance), can partly be 
explained by the “mitochondrial threshold effect” (Rossignol et al., 2003). The significant 
correlation between the proportion of apoptotic muscle fibres and the proportion of mutant mtDNA 
exemplifies this hypothesis (Aure et al., 2006). It is known that the mitochondrial copy number can 
compensate and can be increased by physical exercise, implying the mutation load is not the only 
factor involved. Like muscle cells, neurons are post-mitotic and therefore are likely to behave 
similarly. Comparable mutation loads were detected across several brain regions to those in skeletal 
muscle. However, it is not known how the mutation load in neurons develops over lifetime (Betts et 
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al., 2006). We have found that the mutation load in blood is a better marker for cognitive 
performances and brain functioning in m.3243A>G patients than the mutation load in UECs, even 
though both mutation loads are correlated to each other. The reason for this discrepancy is 
unknown, but may be specific to the age-range of the current patient population.  
 
4.2. Brain morphological markers of the m.3243A>G mutation 
 The current results present strong evidence of a mutation load effect within the patient 
population on global brain volume, in addition to widespread lower brain volume in the patients 
compared to controls. While patients with a low mutation load are characterized by normal-
appearing brains, stronger brain atrophy is observed in patients with higher mutation load. This was 
especially apparent in the cortical and cerebellar GM, but not for the subcortical structures, which is 
in accordance with biochemical analyses of post-mortem brains (Sparaco et al., 2003). Strongest 
local cGM atrophy and reduced cortical thickness as a function of m.3243A>G mutation load was 
observed in regions linked to: (i) auditory processing (superior temporal cortices), (ii) attentional 
control (middle frontal and parietal gyri and anterior cingulate cortices), (iii) sensorimotor network 
(central sulci and neighbouring gyri) and (iv) default mode network (precuneus). These latter two 
structures were also observed by a recent study that used voxel-based morphometry to characterize 
morphological differences between m.3243A>G patients and healthy controls (Tsujikawa et al., 
2016). Notably, significant local correlations, after correction for multiple comparisons, between 
cortical thickness and mutation load were only found for values from the blood. 
 
The neuropathological effects of the mutation load in some brain areas, but not in others, 
signify the differential abilities of neurons to survive respiratory chain deficiencies (Betts et al., 
2006). More work has to be performed, particularly using invasive cellular methods, to establish the 
link between mitochondrial dysfunction and macroscopic brain changes, as detected with non-
invasive MRI. Nevertheless, the observed brain patterns can be readily related to the different 
clinical symptoms often observed in m.3243A>G patients, such as the currently high prevalence of 
hearing impairment. Since auditory brainstem responses are often preserved, it is likely of cochlear 
origin (Kullar et al., 2016). In addition, the severity of the hearing loss correlates with the mutation 
load, being worse in patients with a higher mutation load (Chinnery et al., 2000). Therefore, 
decreasing cortical thickness and atrophy in the regions linked to auditory processing (auditory 
cortex, planum temporale and superior temporal sulcus and gyrus) with increasing m.3243A>G 
mutation load, are most likely caused by impaired cochlear functioning (Eckert et al., 2012; 
Formisano et al., 2008; Syka, 2002).  
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Even though the cortical thinning in the auditory regions may predominantly occur after 
cochlear damage, the morphological differences in the other affected brain regions may be induced 
through direct interferences of the mutation on neuronal integrity through, for example, neuronal 
hyperexcitability (Iizuka et al., 2003; Iizuka et al., 2002). Impaired mitochondrial protein (i.e. 
OXPHOS subunits) synthesis due to a defective tRNALeu(UUR) has been shown in the cerebral 
and cerebellar cortex of post-mortem m.3243A>G brains (Sparaco et al., 2003). Here, changes were 
mostly found in the intermediate layers of cGM regions, with a higher degree of cellular 
dependence on oxidative metabolism, and in the cerebellar Purkinje cells, respectively. As such, 
neuronal changes may occur especially in brain regions characterized by a high (baseline) energy 
demand and/or functional connectivity or cerebellum (i.e. metabolic hypothesis), depending on the 
mutation load similar to that observed in skeletal muscle cells (Aure et al., 2006). These high 
energy consuming brain areas include regions related to the default mode, dorsal attention and 
sensorimotor networks (Tomasi et al., 2013), in agreement with our findings of atrophy in these 
regions, such as in the precuneus, middle frontal gyrus and central sulcus (somatosensory and motor 
cortices), respectively. The cortical thinning observed in regions associated with attentional 
control/executive functioning, such as the middle frontal and parietal gyri and anterior cingulate 
cortices (Milham et al., 2002), are consistent with behavioural symptoms, e.g. patients with a higher 
mutation load performed worse on the Stroop task. In particular, OXPHOS deficits-susceptible 
inhibitory interneurons may play a prominent role in the cognitive dysfunctioning observed in 
mitochondrial disease patients (Finsterer, 2012; Lax et al., 2016). 
 
Comparable to the cGM atrophy, cerebellar GM atrophy was most pronounced in the high 
mutation load group compared to patients with a lower mutation load, quantified by a volume loss 
or illustrated by larger inter-folial spaces. Previously, studies have shown that the cerebellum is 
highly vulnerable to mitochondrial dysfunctioning (Scaglia et al., 2005) due to respiratory chain 
deficiencies of complex I and IV, leading to cerebellar atrophy by Purkinje and granule cell loss 
(Lax et al., 2012; Sparaco et al., 2003). This is consistent with the fact that cerebellar ataxia is 
commonly described in mtDNA patients (de Laat et al., 2012; Lax et al., 2012). As for cerebellar 
GM, smaller subcortical volume was observed for the patients compared to the healthy controls, in 
particular in the Pu and GP (i.e. lentiform nucleus), structures especially involved in motor 
execution (Middleton and Strick, 2000). The volume loss correlates with the described neuronal 
vacuolization (i.e. spongiosis) in both these structures for several patients, potentially resulting from 
abnormalities within the vascular smooth muscle and endothelial cells (i.e. vascular hypothesis, 
Betts et al. (2006)) or from astroglial pathogenesis (Bugiani et al., 2017; van der Knaap et al., 
2012). However, in contrast to the cortical and cerebellar GM, the mutation load did not affect the 
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degree of subcortical atrophy. This may implicate that the causal mechanism is different compared 
to that underlying cortical atrophy (e.g. vascular vs. metabolic hypotheses). Generally, by taking 
together the cortical atrophy in sensorimotor regions, subcortical (i.e. lentiform nucleus) and 
cerebellar GM volume losses, the current results suggest a global brain-wide impaired motor 
functioning (Seidler et al., 2015). These changes are excellent brain correlates to some of the 
symptoms often observed in m.3243A>G and mitochondrial disease patients, such as cerebellar 
(and/or sensory) ataxia and gait instability (de Laat et al., 2012).     
 
4.3. Cortical microstructure- and metabolic-related markers of the m.3243A>G 
mutation 
Besides macroscopic morphological differences, T1, T2* and CBF significantly varied (i.e. 
increased) as a function of mutation load in several cGM regions. Differences in quantitative T1 and 
T2* across the brain are predominantly attributed to varying myelin and iron content between brain 
structures and regions (Stuber et al., 2014). In line with earlier work that showed delayed or 
decreased myelination in patients affected by respiratory chain defects (Dinopoulos et al., 2005; 
Lax et al., 2016; Sofou et al., 2013), positive correlations between T1 and T2* values with mutation 
load within the patient population were observed, in particular in the primary- and heavily-
myelinated regions of the cGM, including the somatosensory- and motor cortices (Haast et al., 
2016), but also in cerebellar GM. In general, increased T1 and T2* implicate lower levels of myelin 
(Stuber et al., 2014). Decreased myelin synthesis, due to the defective cellular energy production 
during the critical time of myelin development in early life, may have resulted in the increasing T1 
and T2* with mutation load. Furthermore, we observed higher CBF in the subcortical structures as 
well as in the superior frontal gyrus, for patients with a higher mutation load. These effects could be 
induced (i) by the altered vascular functionality (e.g. related to the subcortical spongiosis and 
vascular abnormalities), (ii) by a compensatory mechanism for the impaired neuronal energy 
production or (iii) as an attempt to reduce the increased brain lactate (or other potentially harmful 
compounds) levels, as argued by Rodan et al. (2015).  
 
However, when the patient populations are compared against controls, surprisingly, the 
metabolic-, but also microstructural-related characteristics do not follow the expected linear change 
as a function of mutation load, but a U-shaped dependency across groups. That is, MRI values over 
the entire cortex of Phigh patients and healthy subjects are similarly different than those of the Plow 
patients. Two hypotheses could explain this observed pattern: i) the dip in cortical CBF, T1 and T2* 
values for the Plow patients may signify that certain compensatory mechanisms are initiated only in 
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the Phigh patients (i.e. mitochondrial threshold effect). That is, for the Plow group, there is only a mild 
loss in e.g. myelination, which does not evoke/necessitate activation of local molecular pathways to 
compensate for this loss. However, for the Phigh group, compensatory mechanisms are necessary to 
maintain functioning of the respective brain area. In fact, delayed myelination in the Phigh group, as 
described above, may have led to global myelination levels similar to control ranges, as suggested 
by the correspondence between the range of T1 and T2* values observed in the group-wise 
comparison between controls and patients, confirming earlier claims (Dinopoulos et al., 2005; 
Sofou et al., 2013). Alternatively, ii) T1, T2* and brain metabolic changes have many biochemical 
and microscopic contributions, which do not have to follow the same dependency on mutation load. 
For example, T1 increases as a function of both myelin and iron. That is, a decrease in myelin has an 
opposing effect on the resulting T1 values than an increase in iron content, and the latter change is a 
common observation in many neurodegenerative diseases. Thus, it is reasonable to assume that 
myelination decreases and iron content increases as a function of mutation load but they have 
different dependencies on the m.3243A>G mutation load, leading to the U-shape function observed 
pattern for T1. In contrast to the observed cortical pattern, the increased cerebellar GM T1 observed 
in patients compared to controls, in addition to the unchanged T2*, may implicate predominantly 
myelin loss secondary to neuronal and axonal loss (Lax et al., 2012; Virtanen et al., 2011).  
 
Interestingly, T1 and T2* differences in the subcortical structures were absent, which is 
indicative for subcortical biochemical changes that may be more specific for certain mtDNA 
mutations (Barragan-Campos et al., 2005; Bindu et al., 2015). This is in sharp contrast to previously 
observed subcortical T1w and T2w changes (Tschampa et al., 2013). However, it is important to note 
that most of the available MRI studies on mitochondrial diseases, if not all, employed data acquired 
using conventional clinical, non-quantitative MRI approaches, such as FLAIR. These do not 
provide quantitative markers of the underlying biochemical composition of the tissue, as the MRI 
signal intensity are additionally influenced by MRI sequence parameters and the hardware setup 
(such as transmit and receive imaging coils) (Bock et al., 2013; Lorio et al., 2016). Moreover, 
clinical scans typically have anisotropic voxel sizes, increasing partial voluming effects and mixing 
signals originating from WM and GM or spongiotic tissue and subcortical GM. Therefore, 
quantitative interpretation of data acquired for diagnostic purposes is challenging, as interpretations 
of such data contributions are confounded by many other MRI acquisition and physiological 
parameters (e.g. transmit and receive RF fields, proton density, relaxation rates, macromolecule 
concentrations (Haast et al., 2016)). In summary, these results exemplify the benefits of a multi-
parametric MRI protocol, as they allow discerning the biochemical causes of brain changes in 
disease and reliable intra- and inter-subject comparisons. 
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5. Conclusions 
In conclusion, the current work utilized high-resolution MRI data acquired using 7T MRI to 
quantify brain changes in a representative population of m.3243A>G patients. The data revealed 
neuroradiological (i.e. morphology, microstructure- and metabolism-related) changes in patients 
with varying levels of mutation load, including those with a mutation load lower than previously 
observed threshold levels, compared to healthy controls (see Supplementary Table 2 for an 
overview). Interestingly, mutation load in blood compared to UECs provides a better estimate of the 
brain changes. The observed changes are widespread, but mainly affect GM, and are consistent with 
the different clinical symptoms. However, the underlying biological mechanisms and timing may 
vary across brain structures/regions. Our results, thus, indicate the value of quantitative MRI at 7T 
to determine pathological effects of the m.3243A>G mutation on brain structure and function for 
various mutation loads. Future longitudinal quantitative MRI but also in vitro studies are necessary 
to track the progression of the detected MRI-based biomarkers to improve the understanding of the 
disease pathogenesis and clinical symptoms development.  
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Highlights 
 Quantitative 7T MRI was used to describe the m.3243A>G genotype-brain relationship 
 This is the first 7T and also the largest MRI study on this patient population 
 Cortical thickness, T1, T2* and CBF changed locally as a function of mutation load 
 They can be linked to clinical symptoms observed in m.3243A>G patients 
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